---
layout: default
title: Flucloxacillin
parent: 僅模型預測 (L5)
nav_order: 265
evidence_level: L5
indication_count: 10
---

# Flucloxacillin
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Flucloxacillin: From Staphylococcal Infections to Conjunctivitis

## One-Sentence Summary

Flucloxacillin is an antistaphylococcal penicillin whose formally approved indication text is not on file for Saudi Arabia (the drug is currently not marketed there). The TxGNN model predicts it may be effective for **Conjunctivitis**, but this is currently supported by **0 clinical trials** and only **3 publications**, none of which directly studies flucloxacillin for this indication.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not on file — drug not marketed in Saudi Arabia; drug class is antistaphylococcal penicillin (per evidence-pack rationale) |
| Predicted New Indication | Conjunctivitis |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L4 |
| Saudi Arabia Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available for flucloxacillin in this evidence pack (flagged as a High-severity data gap). Based on the information that is available, flucloxacillin is an antistaphylococcal β-lactam antibiotic — its established role is treating infections caused by *Staphylococcus aureus* and other susceptible Gram-positive organisms.

Bacterial conjunctivitis, particularly the staphylococcal subtype, is theoretically a plausible target for an antistaphylococcal agent. However, the three literature hits returned for this pairing do not actually study flucloxacillin's efficacy in conjunctivitis: one is a case report of gonococcal dacryoadenitis (a different pathogen, no drug link), one is a review of staphylococcal scalded skin syndrome that mentions conjunctivitis only as a prodromal symptom (not a treatment study), and one is a review of atypical herpes simplex presentations with no connection to flucloxacillin at all. This pattern is consistent with TxGNN generating a high score from topic co-occurrence (staphylococcal disease, ophthalmic infection) rather than from a genuine treatment signal.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [41884366](https://pubmed.ncbi.nlm.nih.gov/41884366/) | 2026 | Case Report | Case reports in ophthalmology | Gonococcal dacryoadenitis case; pathogen is *N. gonorrhoeae*, not staphylococcal — no direct relevance to flucloxacillin |
| [12627992](https://pubmed.ncbi.nlm.nih.gov/12627992/) | 2003 | Review | American journal of clinical dermatology | Review of staphylococcal scalded skin syndrome; notes conjunctivitis as a prodromal symptom, not a treatment outcome |
| [1286123](https://pubmed.ncbi.nlm.nih.gov/1286123/) | 1992 | Review | International journal of STD & AIDS | Review of atypical HSV presentations; no mention of flucloxacillin or bacterial conjunctivitis treatment |

## Saudi Arabia Market Information

Flucloxacillin currently has no registered market authorization in Saudi Arabia (0 licenses on file).

## Safety Considerations

Please refer to the package insert for safety information. Note: SFDA package insert warnings/contraindications and drug-interaction data could not be retrieved in this evidence pack (Blocking data gap — DG001), so a full safety evaluation cannot yet be completed.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The predicted indication is not supported by any clinical trial and only by literature that does not directly address flucloxacillin's use in conjunctivitis. Combined with a Blocking-severity gap in safety data (SFDA warnings/contraindications), this candidate cannot proceed past initial screening.

**To proceed, the following is needed:**
- SFDA package insert (warnings, contraindications, DDI) — currently blocking safety evaluation (DG001)
- Mechanism-of-action detail from DrugBank (DG002)
- Targeted literature/trial search specifically on flucloxacillin efficacy in bacterial/staphylococcal conjunctivitis, rather than general co-occurrence hits
- Clarification of Saudi Arabia registration status for flucloxacillin generally, given it is currently unmarketed
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

